162 related articles for article (PubMed ID: 15210041)
21. Tumor M2 pyruvate kinase: a tumor marker and its clinical application in gastrointestinal malignancy.
Hardt PD; Ewald N
Expert Rev Mol Diagn; 2008 Sep; 8(5):579-85. PubMed ID: 18785806
[TBL] [Abstract][Full Text] [Related]
22. Quantification of tumor type M2 pyruvate kinase (Tu M2-PK) in human carcinomas.
Eigenbrodt E; Basenau D; Holthusen S; Mazurek S; Fischer G
Anticancer Res; 1997; 17(4B):3153-6. PubMed ID: 9329624
[TBL] [Abstract][Full Text] [Related]
23. Tumour M2-pyruvate kinase: a gastrointestinal cancer marker.
Kumar Y; Tapuria N; Kirmani N; Davidson BR
Eur J Gastroenterol Hepatol; 2007 Mar; 19(3):265-76. PubMed ID: 17301655
[TBL] [Abstract][Full Text] [Related]
24. [Tumor M2 pyruvate kinase in renal cell carcinoma. Studies of plasma in patients].
Roigas J; Schulze G; Raytarowski S; Jung K; Schnorr D; Loening SA
Urologe A; 2000 Nov; 39(6):554-6. PubMed ID: 11138278
[TBL] [Abstract][Full Text] [Related]
25. Diagnostic value of tumor M2-pyruvate kinase in neuroendocrine tumors. A comparative study with chromogranin A.
Pezzilli R; Migliori M; Morselli-Labate AM; Campana D; Ventrucci M; Tomassetti P; Corinaldesi R
Anticancer Res; 2003; 23(3C):2969-72. PubMed ID: 12926146
[TBL] [Abstract][Full Text] [Related]
26. Tumor M2-pyruvate kinase: a promising tumor marker in the diagnosis of gastro-intestinal cancer.
Hardt PD; Ngoumou BK; Rupp J; Schnell-Kretschmer H; Kloer HU
Anticancer Res; 2000; 20(6D):4965-8. PubMed ID: 11326648
[TBL] [Abstract][Full Text] [Related]
27. A comparison of tumour M2-PK with carcinoembryonic antigen and CA19-9 in patients undergoing liver resection for colorectal metastases.
Kumar Y; Pinedo IR; Tapuria N; Zabron A; Davidson BR
Eur J Gastroenterol Hepatol; 2008 Oct; 20(10):1006-11. PubMed ID: 18787469
[TBL] [Abstract][Full Text] [Related]
28. The tumor marker tumor M2-PK: an application in the diagnosis of gastrointestinal cancer.
Schulze G
Anticancer Res; 2000; 20(6D):4961-4. PubMed ID: 11326647
[TBL] [Abstract][Full Text] [Related]
29. Serum tissue polypeptide specific antigen (TPS) in patients with cervical carcinoma: preliminary report.
Pattaranutaporn P; Chansilpa Y; Tangkarat S; Tepmongkol P; Sangruchi S; Senapad S
Anticancer Res; 1997; 17(3C):2309-12. PubMed ID: 9216707
[TBL] [Abstract][Full Text] [Related]
30. Tumor marker M2-pyruvate-kinase in differential diagnosis of chronic pancreatitis and pancreatic cancer.
Novotný I; Dítĕ P; Dastych M; Záková A; Trna J; Novotná H; Nechutová H
Hepatogastroenterology; 2008; 55(85):1475-7. PubMed ID: 18795715
[TBL] [Abstract][Full Text] [Related]
31. Plasma levels of tumor M2-pyruvate kinase should not be used as a tumor marker for hematological malignancies and solid tumors.
Staib P; Hoffmann M; Schinköthe T
Clin Chem Lab Med; 2006; 44(1):28-31. PubMed ID: 16375581
[TBL] [Abstract][Full Text] [Related]
32. Value of the serum levels of the tumor marker TUM2-PK in pancreatic cancer.
Oremek GM; Eigenbrodt E; Rädle J; Zeuzem S; Seiffert UB
Anticancer Res; 1997; 17(4B):3031-3. PubMed ID: 9329593
[TBL] [Abstract][Full Text] [Related]
33. Improved sensitivity in the diagnosis of gastro-intestinal tumors by fuzzy logic-based tumor marker profiles including the tumor M2-PK.
Schneider J; Bitterlich N; Schulze G
Anticancer Res; 2005; 25(3A):1507-15. PubMed ID: 16033052
[TBL] [Abstract][Full Text] [Related]
34. [The significance of TU M2-PK tumor marker for lung cancer diagnostics].
Oremek G; Kukshaĭte R; Sapoutzis N; Ziolkowski P
Klin Med (Mosk); 2007; 85(7):56-8. PubMed ID: 17882813
[TBL] [Abstract][Full Text] [Related]
35. Comparison of tumor M2-pyruvate kinase (tumor M2-PK), carcinoembryonic antigen (CEA), carbohydrate antigens CA 19-9 and CA 72-4 in the diagnosis of gastrointestinal cancer.
Schneider J; Schulze G
Anticancer Res; 2003; 23(6D):5089-93. PubMed ID: 14981971
[TBL] [Abstract][Full Text] [Related]
36. Plasma TM2-PK levels in mycosis fungoides patients.
Hapa A; Erkin G; Hasçelik G; Pektaş D; Arslan U
Arch Dermatol Res; 2011 Jan; 303(1):35-40. PubMed ID: 20927531
[TBL] [Abstract][Full Text] [Related]
37. Fecal pyruvate kinase concentrations (ELISA based on a combination of clone 1 and clone 3 antibodies) for gastric cancer screening.
Hardt PD; Toepler M; Ngoumou B; Rupp J; Kloer HU
Anticancer Res; 2003; 23(2A):855-7. PubMed ID: 12820313
[TBL] [Abstract][Full Text] [Related]
38. Tumor M2-PK levels in haematological malignancies.
Oremek GM; Rox S; Mitrou P; Sapoutzis N; Sauer-Eppel H
Anticancer Res; 2003; 23(2A):1135-8. PubMed ID: 12820361
[TBL] [Abstract][Full Text] [Related]
39. Tumor M2 pyruvate kinase in plasma of patients with urological tumors.
Roigas J; Schulze G; Raytarowski S; Jung K; Schnorr D; Loening SA
Tumour Biol; 2001; 22(5):282-5. PubMed ID: 11553857
[TBL] [Abstract][Full Text] [Related]
40. Early predicting recurrent cervical cancer with combination of tissue polypeptide specific antigen (TPS) and squamous cell carcinoma antigen (SCC).
Hung YC; Shiau YC; Chang WC; Kao CH; Lin CC
Neoplasma; 2002; 49(6):415-7. PubMed ID: 12584591
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
